Jordi To-Figueras

Jordi To-Figueras

Auto-generated profile, based on publicly available information

Jordi To-Figueras

Department of Biochemistry and Molecular Genetics, CDB, Hospital Clínic de Barcelona, University of Barcelona

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
JTJordi To‐Figueras
Jordi To‐Figueras
RWRobin Wijngaard
Robin Wijngaard
JGJudit García‐Villoria
Judit García‐Villoria
AAAasne K. Aarsand
Aasne K. Aarsand
PAPaula Aguilera
Paula Aguilera
SSSverre Sandberg
Sverre Sandberg

1 August 2017 in Journal of Chromatography B
Verified
Journal Article
Closed access
AGAlex Gomez-Gomez
Alex Gomez-Gomez
JMJosep Marcos
Josep Marcos
PAPaula Aguilera
Paula Aguilera
JTJordi To-Figueras
Jordi To-Figueras
Oscar PozoOscar Pozo
Oscar Pozo

28 June 2024 in Liver International
Verified
Journal Article
Open access
AAAasne K. Aarsand
Aasne K. Aarsand
JTJordi To‐Figueras
Jordi To‐Figueras
SWSharon Whatley
Sharon Whatley
SSSverre Sandberg
Sverre Sandberg
CSCaroline Schmitt
Caroline Schmitt
The porphyrias are a group of rare inborn errors of metabolism associated with various clinical presentations and long‐term complications, making them relevant differential diagnoses to consider for many clinical specialities, especially hepatologists, gastroenterologists and dermatologists. To diagnose a patient with porphyria requires appropriate biochemical investigations, as clinical features alone are not specific enough. Furthermore, it is important to be aware that abnormalities of porphyrin accumulation and excretion occur in many other disorders that are collectively far more common than the porphyrias. In this review, we provide an overview of porphyria‐related tests with their strengths and limitations, give recommendations on requesting and diagnostic approaches in non‐expert and expert laboratories for different clinical scenarios and discuss the role of genetic testing in the porphyrias. To diagnose porphyria in a currently symptomatic patient requires analysis of biochemical markers to demonstrate typical patterns of haem precursors in urine, faeces and blood. The use of genomic sequencing in diagnostic pathways for porphyrias requires careful consideration, and the demonstration of increased porphyrin‐related markers is necessary prior to genomic testing in symptomatic patients. In the acute porphyrias, genomic testing is presently a useful adjunct for genetic counselling of asymptomatic family members and the most common cutaneous porphyria, porphyria cutanea tarda, is usually a sporadic, non‐hereditary disease. Getting a correct and timely porphyria diagnosis is essential for delivering appropriate care and ensuring best patient outcome.

1 November 2019 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
BCBrenden Chen
Brenden Chen
SWSharon Whatley
Sharon Whatley
MBMichael Badminton
Michael Badminton
AAAasne K. Aarsand
Aasne K. Aarsand
KAKarl Elmo Anderson
Karl Elmo Anderson
RDRobert J. Desnick
Robert J. Desnick

1 November 2019 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
JTJordi To-Figueras
Jordi To-Figueras

8 May 2024 in Liver International
Verified
Journal Article
Closed access
JTJordi To‐Figueras
Jordi To‐Figueras
AEAngelika L. Erwin
Angelika L. Erwin
PAPaula Aguilera
Paula Aguilera
Oscar MilletOscar Millet
Oscar Millet
RDRobert J. Desnick
Robert J. Desnick